These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 2525310)

  • 21. The benzazepine, SCH 23390, inhibits 3H-NPA binding in mouse brain in vivo.
    Andersen PH; Nielsen EB
    Acta Pharmacol Toxicol (Copenh); 1986 Oct; 59(4):315-8. PubMed ID: 2948372
    [TBL] [Abstract][Full Text] [Related]  

  • 22. D2 receptor occupancy in conscious rat brain is not significantly distinguished with [3H]-MNPA, [3H]-(+)-PHNO, and [3H]-raclopride.
    Peng T; Zysk J; Dorff P; Elmore CS; Ström P; Malmquist J; Ding M; Tuke D; Werkheiser J; Widzowski D; Mrzljak L; Maier D
    Synapse; 2010 Aug; 64(8):624-33. PubMed ID: 20340171
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evidence for the existence of receptor--receptor interactions in the central nervous system. Studies on the regulation of monoamine receptors by neuropeptides.
    Fuxe K; Agnati LF; Benfenati F; Celani M; Zini I; Zoli M; Mutt V
    J Neural Transm Suppl; 1983; 18():165-79. PubMed ID: 6192208
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dopamine D2High receptors measured ex vivo are elevated in amphetamine-sensitized animals.
    Seeman P
    Synapse; 2009 Mar; 63(3):186-92. PubMed ID: 19086090
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ACTH/MSH-like peptides inhibit the binding of dopaminergic ligands to the dopamine D2 receptor in vitro.
    Florijn WJ; De Boer T; Tonnaer JA; Van Nispen JW; Versteeg DH
    Eur J Pharmacol; 1991 May; 207(1):43-50. PubMed ID: 1680721
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Modulation of dopamine D3 receptor binding by N-ethylmaleimide and neurotensin.
    Liu Y; Hillefors-Berglund M; von Euler G
    Brain Res; 1994 Apr; 643(1-2):343-8. PubMed ID: 7913398
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dopamine receptor binding in bovine intermediate lobe pituitary membranes.
    Sibley DR; Creese I
    Endocrinology; 1980 Nov; 107(5):1405-9. PubMed ID: 7428676
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In situ molecular size of agonist dopamine D-2 binding sites in rat striatum.
    Gredal O; Nielsen M
    J Neurochem; 1987 Feb; 48(2):364-9. PubMed ID: 3794711
    [TBL] [Abstract][Full Text] [Related]  

  • 29. R(-)2-fluoro-N-n-propylnorapomorphine: a very potent and D2-selective dopamine agonist.
    Baldessarini RJ; Kula NS; Gao Y; Campbell A; Neumeyer JL
    Neuropharmacology; 1991 Jan; 30(1):97-9. PubMed ID: 1675452
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synaptic concentration of dopamine in the mouse striatum in relationship to the kinetic properties of the dopamine receptors and uptake mechanism.
    Ross SB
    J Neurochem; 1991 Jan; 56(1):22-9. PubMed ID: 1824780
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cholecystokinin peptides in vitro modulate the characteristics of the striatal 3H-N-propylnorapomorphine sites.
    Agnati LF; Celani MF; Fuxe K
    Acta Physiol Scand; 1983 May; 118(1):79-81. PubMed ID: 6312748
    [No Abstract]   [Full Text] [Related]  

  • 32. l-Glutamate reduces the affinity of [3H]N-propylnorapomorphine binding sites in striatal membranes.
    Fuxe K; Celani MF; Martire M; Zini I; Zoli M; Agnati LF
    Eur J Pharmacol; 1984 Apr; 100(1):127-30. PubMed ID: 6144551
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neurotensin peptides antagonistically regulate postsynaptic dopamine D2 receptors in rat nucleus accumbens: a receptor binding and microdialysis study.
    Li XM; Ferraro L; Tanganelli S; O'Connor WT; Hasselrot U; Ungerstedt U; Fuxe K
    J Neural Transm Gen Sect; 1995; 102(2):125-37. PubMed ID: 8748677
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Autoradiographic localization and quantification of dopamine D2 receptors in normal human brain with [3H]N-n-propylnorapomorphine.
    Camus A; Javoy-Agid F; Dubois A; Scatton B
    Brain Res; 1986 Jun; 375(1):135-49. PubMed ID: 3719352
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Persistent effects of subchronic toluene exposure on spatial learning and memory, dopamine-mediated locomotor activity and dopamine D2 agonist binding in the rat.
    von Euler G; Ogren SO; Li XM; Fuxe K; Gustafsson JA
    Toxicology; 1993 Mar; 77(3):223-32. PubMed ID: 8096348
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Kainate lesion dissociates striatal dopamine receptor radioligand binding sites.
    Leff S; Adams L; Hyttel J; Creese I
    Eur J Pharmacol; 1981 Mar; 70(1):71-5. PubMed ID: 7215442
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cholecystokinin octapeptide in vitro and ex vivo strongly modulates striatal dopamine D2 receptors in rat forebrain sections.
    Li XM; Hedlund PB; Fuxe K
    Eur J Neurosci; 1995 May; 7(5):962-71. PubMed ID: 7613631
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dopamine receptor binding sites in the rat superior colliculus.
    Chivers JK; Hall MD; Kelly E; Jenner P; Marsden CD
    J Pharm Pharmacol; 1984 Jul; 36(7):484-8. PubMed ID: 6146700
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of temperature on the in vitro binding of 3H-raclopride to rat striatal dopamine-D2 receptors.
    Hall H; Wedel I; Sallemark M
    Pharmacol Toxicol; 1988 Aug; 63(2):118-21. PubMed ID: 2973009
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intraventricular injection of neurotensin reduces the binding of dopamine D-2 receptors in the rat forebrain.
    von Euler G; Meister B; Hökfelt T; Fuxe K
    Acta Physiol Scand; 1989 Oct; 137(2):309-10. PubMed ID: 2618764
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.